ctx110
crispr,crispr
['carbon trial', 'crispr']
we're pleased to provide an update for both part a and part b of our ongoing phase 1 carbon trial evaluating the safety and efficacy of ctx110 , our wholly-owned allogeneic car t cell therapy targeting cd19+ b-cell malignancies. learn more: #ash22 